Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2009. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on November 10, 2009, at a price of £12.36 per share through the Company's Share Reward Plan. Each individual acquired 10 shares via a personal contribution (partnership element) and 10 shares via a company contribution (matching element). No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of share purchases in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £12.36 per Ordinary share on November 10, 2009.
- Confirm the total number of shares acquired by each listed director (20 shares per person: 10 personal, 10 matched).
- Review the full list of participating directors: A P Witty, J S Heslop, S M Bicknell, E J Gray, S A Hussain, D Learmouth, D S Redfern, and C Thomas.
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.